Case Report: Dual checkpoint inhibition with bevacizumab yields dramatic response in synchronous double primary HCC and ICC with lung metastasis
Our study reports the first case that systematic therapy achieved successful conversion therapy in an unresectable sdpHCC-ICC. Combination immunotherapy might represent a promising therapeutic strategy for sdpHCC-ICC, warranting further validation.
Authors
- Qingyun Xie (ORCID: https://orcid.org/0009-0003-1621-7589)
- Xiaonan Dai (ORCID: https://orcid.org/0009-0003-8482-5316)
- Fengwei Gao (ORCID: https://orcid.org/0000-0002-1385-0237)
- Yunshi Cai (ORCID: https://orcid.org/0000-0003-1360-3217)
- Yuxia He (ORCID: https://orcid.org/0000-0002-4470-6342)
- Xiao‐Juan Yang (ORCID: https://orcid.org/0000-0002-0869-4460)
- Tian Lan (ORCID: https://orcid.org/0000-0001-7713-5411)
- Sinan Xie (ORCID: https://orcid.org/0009-0005-5695-3075)
- Yinghao Lv
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-24
- DOI
- https://doi.org/10.3389/fonc.2025.1670818
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00